Prostate specific antigen density of the transition zone for early detection of prostate cancer

被引:99
|
作者
Djavan, B [1 ]
Zlotta, AR
Byttebier, G
Shariat, S
Omar, M
Schulman, CC
Marberger, M
机构
[1] Univ Hosp Vienna, Dept Urol, Vienna, Austria
[2] Univ Clin Brussel, Erasme Hosp, Dept Urol, Brussels, Belgium
来源
JOURNAL OF UROLOGY | 1998年 / 160卷 / 02期
关键词
prostate-specific antigen; prostatic neoplasms;
D O I
10.1016/S0022-5347(01)62911-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We compare the ability of several prostate specific antigen (PSA) parameters, including PSA density of the whole prostate and of the transition zone, percent free PSA and PSA velocity, to enhance the specificity for prostate cancer detection and to reduce unnecessary biopsies in men with serum PSA levels of 4 to 10.0 ng./ml. Materials and Methods: This prospective study included 559 consecutive men referred for early prostate detection or lower urinary tract symptoms who had a serum PSA of 4.0 to 10.0 ng./ml. All men underwent prostatic ultrasonography and sextant biopsy with 2 additional transition zone biopsies. Specific biopsies of abnormal findings on digital rectal examination were also performed. In all cases if first biopsies were negative an additional set of biopsies was performed within 6 weeks. The ability of PSA density, PSA transition zone, PSA velocity and percent free PSA to improve the power of PSA in the detection of prostate cancer was evaluated with univariate and multivariate analyses as well as receiver operating characteristics (ROC) curves. Results: Of 559 patients 342 had histologically confirmed benign prostatic hyperplasia and 217 had prostate cancer. Mean serum PSA, PSA velocity, PSA density and PSA transition zone were statistically higher (p <0.018, p <0.037, p <0.0001 and p <0.0001, respectively) and percent free PSA was statistically lower (p <0.0001) in patients with prostate cancer than in those with benign disease. Multivariate analysis and ROC curves showed that PSA transition zone and percent free PSA were the most powerful and highly significant predictors of prostate cancer. Areas under the ROC curve for PSA transition zone and percent free PSA were 0.827 and 0.778, respectively (p = 0.01 McNemar test). Combination of free-to-total PSA with PSA transition zone significantly increased the area under the ROC curve compared to PSA transition zone alone (p = 0.020). With a 95% sensitivity for prostate cancer detection a PSA transition zone cutoff of 0.25 ng./ml./cc would result in the lowest number of unnecessary biopsies (47% PSA transition zone specificity) compared to all other PSA parameters. However, total prostate volume (greater than 30 cc in 422 men or less than 30 cc in 137) was an important factor in predicting the statistical performance of PSA transition zone. In fact, PSA transition zone did not outperform free percent PSA in sensitivity and specificity when the entire prostate gland volume was less than 30 cc (p = 0.094 McNemar test). Conclusions: PSA density of the transition zone enhances the specificity of serum PSA for prostate cancer detection in referred patients with a serum PSA of 4.0 to 10.0 ng./ml. compared to other PSA parameters currently available. While PSA transition zone was more effective in prostates greater than 30 cc and percent free PSA was more effective in prostates less than 30 cc, the combination of percent free PSA with PSA transition zone further increased prostate cancer prediction.
引用
收藏
页码:411 / 418
页数:8
相关论文
共 50 条
  • [31] Prostate specific antigen for detecting early prostate cancer
    Ilic, Dragan
    Green, Sally
    BMJ-BRITISH MEDICAL JOURNAL, 2009, 339
  • [32] Prostate specific antigen and screening for early prostate cancer
    Davidson, P
    NEW ZEALAND MEDICAL JOURNAL, 2001, 114 (1129) : 150 - 150
  • [33] COMPARISON OF PROSTATE-SPECIFIC ANTIGEN CONCENTRATION VERSUS PROSTATE-SPECIFIC ANTIGEN DENSITY IN THE EARLY DETECTION OF PROSTATE-CANCER - RECEIVER OPERATING CHARACTERISTIC CURVES
    CATALONA, WJ
    RICHIE, JP
    DEKERNION, JB
    AHMANN, FR
    RATLIFF, TL
    DALKIN, BL
    KAVOUSSI, LR
    MACFARLANE, MT
    SOUTHWICK, PC
    JOURNAL OF UROLOGY, 1995, 154 (03): : 1145 - 1145
  • [34] COMPARISON OF PROSTATE-SPECIFIC ANTIGEN CONCENTRATION VERSUS PROSTATE-SPECIFIC ANTIGEN DENSITY IN THE EARLY DETECTION OF PROSTATE-CANCER - RECEIVER OPERATING CHARACTERISTIC CURVES
    CATALONA, WJ
    RICHIE, JP
    DEKERNION, JB
    AHMANN, FR
    RATLIFF, TL
    DALKIN, BL
    KAVOUSSI, LR
    MACFARLANE, MT
    SOUTHWICK, PC
    JOURNAL OF UROLOGY, 1994, 152 (06): : 2031 - 2036
  • [35] PROSTATE-SPECIFIC ANTIGEN DENSITY - A MEANS TO ENHANCE DETECTION OF PROSTATE-CANCER
    RAMON, J
    BOCCONGIBOD, L
    BILLEBAUD, T
    ASTIER, L
    KOBELINSKY, M
    MEULEMANS, A
    DAUGE, MC
    BOCCONGIBOD, L
    VILLERS, A
    EUROPEAN UROLOGY, 1994, 25 (04) : 288 - 294
  • [36] AN ALGORITHM FOR PROSTATE-CANCER DETECTION IN A PATIENT POPULATION USING PROSTATE-SPECIFIC ANTIGEN AND PROSTATE-SPECIFIC ANTIGEN DENSITY
    BENSON, MC
    MCMAHON, DJ
    COONER, WH
    OLSSON, CA
    WORLD JOURNAL OF UROLOGY, 1993, 11 (04) : 206 - 213
  • [37] Prostate cancer detection at low prostate specific antigen
    Schröder, FH
    van der Cruijsen-Koeter, I
    de Koning, HJ
    Vis, AN
    Hoedemaeker, RF
    Kranse, R
    JOURNAL OF UROLOGY, 2000, 163 (03): : 806 - 811
  • [38] Detection of prostate cancer by prostate-specific antigen
    Egawa, S
    BIOMEDICINE & PHARMACOTHERAPY, 2001, 55 (03) : 130 - 134
  • [39] Value of Prostate Specific Antigen Density and Percent Free Prostate Specific Antigen for Prostate Cancer Prognosis
    Busch, Jonas
    Hamborg, Kristin
    Meyer, Hellmuth-Alexander
    Buckendahl, John
    Magheli, Ahmed
    Lein, Michael
    Jung, Klaus
    Miller, Kurt
    Stephan, Carsten
    JOURNAL OF UROLOGY, 2012, 188 (06): : 2165 - 2170
  • [40] Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng/ml
    Morote, J
    Raventos, CX
    Lorente, JA
    LopezPacios, MA
    Encabo, G
    deTorres, I
    Andreu, J
    JOURNAL OF UROLOGY, 1997, 158 (02): : 502 - 504